Views provided by UsageCountsFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Copyright policy )NIH| VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics ,
NIH| Joint Biology Consortium Resource-based Center ,
NIH| Respiratory Diseases, Genetics, and Rheumatoid Arthritis Risk ,
NIH| Rheumatoid Arthritis and Respiratory Outcomes in Prospective Cohorts
Anja Strangfeld; Martin Schäfer; Milena A Gianfrancesco; Saskia Lawson-Tovey; Jean W Liew; Lotta Ljung; Elsa F Mateus; +193 Authors
Anja Strangfeld; Martin Schäfer; Milena A Gianfrancesco; Saskia Lawson-Tovey; Jean W Liew; Lotta Ljung; Elsa F Mateus; Christophe Richez; Maria J Santos; Gabriela Schmajuk; Carlo A Scirè; Emily Sirotich; Jeffrey A Sparks; Paul Sufka; Thierry Thomas; Laura Trupin; Zachary S Wallace; Sarah Al-Adely; Javier Bachiller-Corral; Suleman Bhana; Patrice Cacoub; Loreto Carmona; Ruth Costello; Wendy Costello; Laure Gossec; Rebecca Grainger; Eric Hachulla; Rebecca Hasseli; Jonathan S Hausmann; Kimme L Hyrich; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Lianne Kearsley-Fleet; Philip C Robinson; Jinoos Yazdany; Pedro M Machado; COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance Consortium Collaborators: COVID-19 Global Rheumatology Alliance Consortium; Brahim Dahou; Marcelo Pinheiro; Francinne M Ribeiro; Anne-Marie Chassin-Trubert; Sebastián Ibáñez; Lingli Dong; Lui Cajas; Hesham Hamoud; Jérôme Avouac; Véronique Belin; Raphaël Borie; Pascal Chazerain; Xavier Chevalier; Pascal Claudepierre; Gaëlle Clavel; Marie-Eve Colette-Cedoz; Bernard Combe; Elodie Constant; Nathalie Costedoat-Chalumeau; Marie Desmurs; Valérie Devauchelle-Pensec; Mathilde Devaux; Robin Dhote; Yannick Dieudonné; Fanny Domont; Pierre-Marie Duret; Mikaël Ebbo; Esther Ebstein; Soumaya El Mahou; Bruno Fautrel; Renaud Felten; René-Marc Flipo; Violaine Foltz; Antoine Froissart; Joris Galland; Véronique Gaud-Listrat; Sophie Georgin-Lavialle; Aude Giraud-Morelet; Jeanine S Giraudet-Le Quitrec; Philippe Goupille; Sophie Govindaraju-Audouard; Franck Grados; Séverine Guillaume-Czitrom; Marion Hermet; Ambre Hittinger-Roux; Christophe Hudry; Isabelle Kone-Paut; Sylvain La Batide Alanore; Pierre Lafforgue; Sophie Lahalle; Isabelle Lambrecht; Vincent Langlois; Jean-Paul Larbre; Emmanuel Ledoult; Christophe Leroux; Frédéric Liote; Alexandre TJ Maria; Hubert Marotte; Arsène Mekinian; Isabelle Melki; Laurent Messer; Catherine Michel; Gauthier Morel; Jacques Morel; Marie-Noelle Paris-Havard; Edouard Pertuiset; Thao Pham; Myriam Renard; Sabine Revuz; Sébastien Rivière; Clémentine Rousselin; Christian Roux; Diane Rouzaud; Jérémie Sellam; Raphaele Seror; Amelie Servettaz; Vincent Sobanski; Christelle Sordet; Lionnel Spielmann; Nathalie Tieulié; Alice Tison; Sophie Trijau; Alexandre Virone; Ursula Warzocha; Daniel Wendling; Frederik N Albach; Peer Aries; Elvira Decker; Urs Hartmann; Joerg Henes; Bimba F Hoyer; Andreas Krause; Klaus Krüger; Hanns-Martin Lorenz; Ulf Müller-Ladner; Alexander Pfeil; Anne Regierer; Jutta G Richter; Markus Rihl; Tim Schmeiser; Hendrik Schulze-Koops; Christof Specker; Reinhard E Voll; Stephanie Werner; Gabriela MG Melgar; Mahdi Vojdanian; Laura Andreoli; Elena Bartoloni-Bocci; Maurizio Benucci; Francesco Campanaro; Marta Caprioli; Davide Carboni; Greta Carrara; Edoardo Cipolletta; Chiara Crotti; Gloria Dallagiacoma; Paola Faggioli; Rosario Foti; Franco Franceschini; Micaela Fredi; Giacomo Guidelli; Florenzo Iannone; Gianpiero Landolfi; Caludia Lomater; Ceciclia Nalli; Simone Parisi; Luca Quartuccio; Bernd Raffeiner; Rossella Reggia; Marta Riva; Nicoletta Romeo; Cinzia Rotondo; Ettore Silvagni; Luigi Sinigaglia; Ilaria Tinazzi; Anna Zanetti; Giovanni Zanframundo; Fatemah Abutiban; Deshiré Alpízar-Rodríguez; Marina R Gabayet; Fedra Irazoque; Xochitl Jimenez; Eduardo Martín; Angel AC Ortiz; Tatiana S Rodriguez-Reyna; Diana C Rosete; Erick AZ Tehozol; David Vega; Beatriz Zaueta; Nasra Al-Adhoubi; Babur Salim; Enrique Giraldo; Ariel Salinas; Manuel Ugarte-Gil; Diogo Almeida; Miguel Bernardes; Rita C Machado; Maria Rato; Samar Al-Emadi; Richard Conway; Rachael Flood;
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
To determine factors associated with COVID-19-related death in people with rheumatic diseases.Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category.Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death.Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.
- Boston College United States
- Comunidad de Madrid Spain
- Assistance Publique -Hopitaux De Paris France
- Boston University United States
- University College London United Kingdom
Glucocorticoids/therapeutic use, Male, 1117 Public Health and Health Services (for), antirheumatic agents, Coronaviruses, Epidemiology, Autoimmune diseases, Registries (mesh), Antirheumatic Agents/therapeutic use, Comorbidity, Cardiovascular, Global Health, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 1103 Clinical Sciences (for), Odds Ratio, Immunology and Allergy, Registries, 32 Biomedical and Clinical Sciences (for-2020), Antirheumatic Agents (mesh), Male (mesh), Arthritis & Rheumatology (science-metrix), Comorbidity (mesh), [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Humans (mesh), [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 3 Good Health and Well Being (sdg), COVID-19 (mesh), glucocorticoids, Rheumatology (mesh), Middle Aged, Arthritis (rcdc), health care, Antirheumatic agents, Infectious Diseases, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antirheumatic Agents, COVID-19/complications, Public Health and Health Services, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, epidemiology, Female, [SDV.IMM] Life Sciences [q-bio]/Immunology, Clinical Sciences, Immunology, 610, 1107 Immunology (for), SARS-CoV-2 (mesh), Autoimmune Disease, General Biochemistry, Genetics and Molecular Biology, Emerging Infectious Diseases (rcdc), Rheumatology, Rheumatic Diseases, 616, Middle Aged (mesh), Humans, Glucocorticoids (mesh), autoimmune diseases, 3204 Immunology (for-2020), outcome assessment, Glucocorticoids, 3202 Clinical Sciences (for-2020), Aged, Autoimmune Disease (rcdc), Cardiovascular (hrcs-hc), Biomedical and Clinical Sciences, Aged (mesh), SARS-CoV-2, Arthritis, Inflammatory and immune system, Rheumatic Diseases (mesh), antirheumatic agents; autoimmune diseases; epidemiology; glucocorticoids; health care; outcome assessment;, Klinisk medicin, Health care, Coronaviruses (rcdc), COVID-19, 3202 Clinical sciences (for-2020), Rheumatology/statistics & numerical data, Odds Ratio (mesh), Arthritis & Rheumatology, Inflammatory and immune system (hrcs-hc), Global Health/statistics & numerical data, Outcome assessment, Rheumatic Diseases/mortality, Emerging Infectious Diseases, Good Health and Well Being, Infectious Diseases (rcdc), COVID-19 Global Rheumatology Alliance, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Female (mesh), antirheumatic agents; autoimmune diseases; epidemiology; glucocorticoids; health care; outcome assessment., [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Global Health (mesh), Clinical Medicine
Glucocorticoids/therapeutic use, Male, 1117 Public Health and Health Services (for), antirheumatic agents, Coronaviruses, Epidemiology, Autoimmune diseases, Registries (mesh), Antirheumatic Agents/therapeutic use, Comorbidity, Cardiovascular, Global Health, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 1103 Clinical Sciences (for), Odds Ratio, Immunology and Allergy, Registries, 32 Biomedical and Clinical Sciences (for-2020), Antirheumatic Agents (mesh), Male (mesh), Arthritis & Rheumatology (science-metrix), Comorbidity (mesh), [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Humans (mesh), [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 3 Good Health and Well Being (sdg), COVID-19 (mesh), glucocorticoids, Rheumatology (mesh), Middle Aged, Arthritis (rcdc), health care, Antirheumatic agents, Infectious Diseases, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antirheumatic Agents, COVID-19/complications, Public Health and Health Services, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, epidemiology, Female, [SDV.IMM] Life Sciences [q-bio]/Immunology, Clinical Sciences, Immunology, 610, 1107 Immunology (for), SARS-CoV-2 (mesh), Autoimmune Disease, General Biochemistry, Genetics and Molecular Biology, Emerging Infectious Diseases (rcdc), Rheumatology, Rheumatic Diseases, 616, Middle Aged (mesh), Humans, Glucocorticoids (mesh), autoimmune diseases, 3204 Immunology (for-2020), outcome assessment, Glucocorticoids, 3202 Clinical Sciences (for-2020), Aged, Autoimmune Disease (rcdc), Cardiovascular (hrcs-hc), Biomedical and Clinical Sciences, Aged (mesh), SARS-CoV-2, Arthritis, Inflammatory and immune system, Rheumatic Diseases (mesh), antirheumatic agents; autoimmune diseases; epidemiology; glucocorticoids; health care; outcome assessment;, Klinisk medicin, Health care, Coronaviruses (rcdc), COVID-19, 3202 Clinical sciences (for-2020), Rheumatology/statistics & numerical data, Odds Ratio (mesh), Arthritis & Rheumatology, Inflammatory and immune system (hrcs-hc), Global Health/statistics & numerical data, Outcome assessment, Rheumatic Diseases/mortality, Emerging Infectious Diseases, Good Health and Well Being, Infectious Diseases (rcdc), COVID-19 Global Rheumatology Alliance, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Female (mesh), antirheumatic agents; autoimmune diseases; epidemiology; glucocorticoids; health care; outcome assessment., [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Global Health (mesh), Clinical Medicine
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).565 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 0.1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 0.1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.01% views 25 - 25views
selected citations
Citations provided by BIP!
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP!influenceInfluence provided by BIP!
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Influence provided by BIP!impulseImpulse provided by BIP!
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
Impulse provided by BIP!viewsViews provided by UsageCounts
Views provided by UsageCounts 565
Top 0.1%
Top 0.1%
Top 0.01%
25
Green
hybrid
